The Carlat Psychiatry Podcast Cobenfy: A New Antipsychotic
11 snips
Oct 7, 2024 Discover the groundbreaking antipsychotic, KarXT, which uniquely doesn't block dopamine, paving new paths in schizophrenia treatment. Dive into its intriguing connections to a 5,000-year-old South Asian herb and the innovative cholinergic effects of xanomaline. The podcast highlights significant clinical trials that reveal KarXT’s efficacy while casting light on its potential advantages over traditional treatments. Addressing both its promise and the uncertainties surrounding its use, it provides a comprehensive look at a fresh hopeful frontier in psychiatry.
AI Snips
Chapters
Transcript
Episode notes
Hurricane Helene Disrupts Conference
- Chris Aiken's talk at the NC Psychiatric Association meeting was disrupted by Hurricane Helene.
- The hotel was damaged, roads closed, and resources became scarce, yet people showed resilience and helped each other.
Cobenfy: A New Antipsychotic
- The FDA approved Cobenfy (KarXT), a new antipsychotic that doesn't block dopamine.
- It's a combination of xanomeline, a muscarinic agonist, and trospium, an anticholinergic for overactive bladder.
Xanomeline's Journey and Betel Leaf
- Xanomeline, initially developed for Alzheimer's, showed promise in reducing psychosis but caused significant cholinergic side effects.
- These side effects led to its discontinuation, but the antipsychotic properties were noticed, linking back to the use of betel leaf in Southern Asia.